- Home
- Products
- Customized ADCs
- FOLR1
- Anti-FOLR1 (M9346A)-SPDB-DM4 ADC
Anti-FOLR1 (M9346A)-SPDB-DM4 ADC (CAT#: ADC-W-516)
This ADC product is comprised of an anti-FOLR1 monoclonal antibody (M9346A) conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM4 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- FOLR1
- Alternative Names
- FOLR1; folate receptor 1 (adult); FBP; FOLR; folate receptor alpha; FR-alpha; KB cells FBP; folate binding protein; folate receptor, adult; adult folate-binding protein; ovarian tumor-associated antigen MOv18;
- Target Entrez Gene ID
- 2348
- Target UniProt ID
- A0A024R5H1
- Overview
- The protein encoded by this gene is a member of the folate receptor family. Members of this gene family bind folic acid and its reduced derivatives, and transport 5-methyltetrahydrofolate into cells. This gene product is a secreted protein that either anchors to membranes via a glycosyl-phosphatidylinositol linkage or exists in a soluble form. Mutations in this gene have been associated with neurodegeneration due to cerebral folate transport deficiency. Due to the presence of two promoters, multiple transcription start sites, and alternative splicing, multiple transcript variants encoding the same protein have been found for this gene.
- Overview
- Humanized Anti-FOLR1 Antibody, M9346A
- Generic name
- M9346A
- Species Reactivity
- Human
- Name
- SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNFRSF10B (Tigatuzumab)-MC-MMAF ADC (CAT#: ADC-W-1882)
- Anti-TNFRSF8 (Brentuximab )-SPDB-DM4 ADC (CAT#: ADC-W-2344)
- Anti-EGFR (clone A1)-Mc-MMAF ADC (CAT#: ADC-W-035)
- Anti-CD22 (Bectumomab)-MC-MMAF ADC (CAT#: ADC-W-796)
- Anti-EPCAM (Edrecolomab)-SMCC-DM1 ADC (CAT#: ADC-W-1094)
- Anti-EGFL7 (Parsatuzumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1032)
- Anti-MUC1 (Pemtumomab)-MC-MMAF ADC (CAT#: ADC-W-2428)
- Anti-ERBB2 (Trastuzumab-HC-F126)-DBCO-MMAF ADC (CAT#: ADC-W-246)
- Anti-IL17A (Secukinumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1315)
- Anti-ST8SIA1 (Mitumomab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1782)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-516. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Linker
Same Payload
Same Target
CAT# | Product Name | Linker | Payload |
ADC-W-2605 | Anti-ITGB3 (Tadocizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2595 | Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-324 | Anti-CD19 (clone huB4)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2590 | Anti-EGFR (Cetuximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2611 | Anti-MS4A1 (Rituximab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-324 | Anti-CD19 (clone huB4)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2621 | Anti-NCAM1 (Lorvotuzumab )-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-469 | Anti-CA6 (clone huDS6)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-2605 | Anti-ITGB3 (Tadocizumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-402 | Anti-FOLR1 (clone M9346A)-sulfo-SPDB-DM4 ADC | sulfo-SPDB | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-1169 | Anti-FOLH1 (Farletuzumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-1166 | Anti-FOLH1 (Farletuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-1168 | Anti-FOLH1 (Farletuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-562 | Anti-FOLR1-DGN462 ADC | maleimide containing linkers | DGN462 |
ADC-W-602 | Anti-FOLR1-S-S-Dox ADC | disulfide (“S-S”) linker | doxorubicin |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.